Abstract
Tyrosine kinase inhibitors exhibit impressive activity against advanced renal cell carcinoma. However, recent clinical studies have shown an equivocal response to sunitinib in patients with castration-resistant prostate cancer. The tumor suppressor PTEN acts as a gatekeeper of the phosphoinositide 3-kinase (PI3K)/ Akt/mTOR cell-survival pathway. Our experiments showed that PTEN expression inversely correlates with sunitinib resistance in renal and prostate cancer cells. Restoration of PTEN expression markedly increases sensitivity of tumor cells to sunitinib both in vitro and in vivo. In addition, pharmacologic manipulation of PI3K/Akt/mTOR signaling with PI3K/mTOR inhibitor, GDC-0980, mTOR inhibitor, temsirolimus, or pan- Akt inhibitor, GSK690693, was able to overcome sunitinib resistance in cancer cells. Our findings underscore the importance of PTEN expression in relation to sunitinib resistance and imply a direct cytotoxic effect by sunitinib on tumor cells in addition to its antiangiogenic actions.
Original language | English |
---|---|
Pages (from-to) | 1510-1517 |
Number of pages | 8 |
Journal | Molecular Cancer Therapeutics |
Volume | 11 |
Issue number | 7 |
DOIs | |
State | Published - Jul 2012 |
Keywords
- Animals
- Antineoplastic Agents/administration & dosage
- Apoptosis/drug effects
- Cell Line, Tumor
- Cytokines/genetics
- Drug Resistance, Neoplasm/genetics
- Humans
- Indoles/administration & dosage
- Kidney Neoplasms/enzymology
- Male
- Mice
- Mice, SCID
- PTEN Phosphohydrolase/genetics
- Prostatic Neoplasms/enzymology
- Proto-Oncogene Proteins c-akt/metabolism
- Pyrroles/administration & dosage
- Signal Transduction/drug effects
- Sunitinib
- TOR Serine-Threonine Kinases/metabolism
- Xenograft Model Antitumor Assays